New Partnership Connects Leadership Excellence to Improved Post-Acute Care
Mobile Health First-to-Market with Fast Track Compliance Hub: Revolutionizing Speed-to-Hire in Post-Acute Care
Exoskeleton Market to be Worth $11.90 Billion by 2031 – Exclusive Report by Meticulous Research®
Altamont Software Installs 500th Connectivity Platform
Parents Gather in Washington, DC to Support McCourt-led People’s Bid for TikTok
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing...
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed...
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE)...
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer,...
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer...
LAS VEGAS, NV, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives Inc. (OTC: BDPT), a leading manufacturer and...
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track...
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update...
– First-in-human clinical trial evaluating QTX3034 as monotherapy and combination in patients with KRASG12D-mutated advanced solid tumors to begin in...
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing...
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored...
VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF,...
Company Funded by Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, Expands Syndicate With Financing from Janus Henderson InvestorsLead...
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with BayerSALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) --...
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP...
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate...
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from...
